Loading
CONKO-005 was the first adjuvant trial to add a targeted drug to chemotherapy after pancreatic surgery; six months of erlotinib with gemcitabine made no difference to the time before relapse (11.4 months in both arms) or to survival.
CONKO-005 randomised 436 patients after R0 resection to gemcitabine 1,000 mg/m2 on days 1, 8 and 15 every four weeks with or without erlotinib 100 mg once daily for six cycles, aiming to lift median disease-free survival from 14 to 18 months. After a median follow-up of 54 months and 361 recurrences, median disease-free survival was 11.4 months in both arms and median overall survival 24.5 months with erlotinib against 26.5 months without; estimated survival at one, two and five years was 77, 53 and 25 percent against 79, 54 and 20 percent, and rash did not predict benefit. Together with the erlotinib arms of LAP07 and RTOG 0848 step 1 it closed the EGFR question in pancreatic cancer outside the licensed metastatic indication.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
436 randomised.
Shares Pancreatic cancer: the failed and stopped programmes and why, Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Charité Universitätsmedizin Berlin, Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy, Pancreatic ductal adenocarcinoma.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Erlotinib, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Charité Universitätsmedizin Berlin, Pancreatic cancer: the failed and stopped programmes and why, Cytotoxic chemotherapy, Pancreatic ductal adenocarcinoma.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Erlotinib, Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine, Small-molecule kinase inhibitors.